Implant Sciences Signs Deal for Up to $5 million with Ryan Security Technologies Ltd. to Expand Sales in China

WILMINGTON, Mass., June 1, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has signed an exclusive distribution agreement, worth up to $5 million, with Ryan Security Technologies Ltd. to manage sales and service of its products throughout all of China.

"We are thrilled to partner with Ryan Security to build on and grow our market reach in China," said Dr. Darryl Jones, Vice President of Global Sales and Marketing. "Ryan has a great reputation and track record of success, which we believe will enable our partnership to leverage the momentum of our ETD technology adoption in the US and Europe to help drive sales in China."

"We believe that Implant Sciences' systems represent the best and most advanced ETD system on the market," said Eric Ryan, President of Ryan Security Technologies.  "We are excited to represent Implant Sciences in China. Their ETD systems and capabilities bring best-in-class security technology to the demanding Chinese market and to meet the needs of security operators." 

"China has and will continue to be a large and important market for our company and technology," added Dr. William McGann, Chief Executive Officer of Implant Sciences Corporation.  "We are very excited about the partnership with Ryan and about our company's future in the Chinese security market as we seek to win sales and grow our global footprint."

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 60 countries worldwide. The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., ECAC in Europe, CAAC and the Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the Interior. It has also received the GSN Homeland Security Award for "Best Explosives Detection Solution" two years in a row (2013 and 2014).  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and any statements of employees, representatives and partners of Implant Sciences Corporation (the "Company") related thereto contain or may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "seeks" or similar expressions.  Such statements are based on management's current expectations and are subject to significant risks and uncertainties (many of which are beyond the Company's control) that could cause the Company's actual results to differ materially from the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risks that there is no guaranty that the Transportation Security Administration (TSA) or any other U.S. or foreign government and law enforcement agencies or commercial consumers (including in China) will purchase any of our explosives detection products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our ability to generate revenue and profit will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K.  In light of these risks and uncertainties, readers are cautioned that actual results may differ significantly from those described or anticipated in the forward-looking statements.  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116  

SOURCE Implant Sciences Corporation

Related Links

http://www.implantsciences.com